2018 年 59 巻 10 号 p. 578-580
In this prospective multicenter study, we evaluate the efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) combination therapy for genotype 1b chronic hepatitis C patients undergoing hemodialysis. Of 17 patients who received GLE/PIB for 8 or 12 weeks, 11 completed the treatment and the 12-week follow-up care that followed. All 11 patients (100%) achieved sustained virologic response 12 (SVR12). Adverse events were observed in 41.2% of all patients and the most frequent adverse event was pruritus. This study suggests that GLE/PIB combination therapy is highly effective and safe even in genotype 1b chronic hepatitis C patients undergoing hemodialysis.